| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000006350 |
| Receipt No. | R000007516 |
| Official scientific title of the study | Preventive effect of aliskiren on migraine complicated with hypertension. |
| Date of disclosure of the study information | 2011/09/16 |
| Last modified on | 2019/01/07 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Preventive effect of aliskiren on migraine complicated with hypertension. | |
| Title of the study (Brief title) | Anti-migraine effect of aliskiren | |
| Region |
|
|
| Condition | ||
| Condition | hypertension
migraine |
|
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Renin-angiotensin modulators are known to possess an anti-migraine effect. The objective of the present study is to determine whether treatment with the direct renin inhibitor aliskiren is effective as a migraine-prophylactic drug.
|
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The number of days with migraine per month |
| Key secondary outcomes | The number of headache attacks per month |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Administration of alisliren | |
| Interventions/Control_2 | Administration of candesartan | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Individuals with informed consent
2. Aged more than 18 years and below 65 years. 3. Hypertensive subjects who satisfy the diagnostic criteria of migraine according to ICHD-II and who have been keeping a headache diary more than one month before entry. 4. Individuals who have had migraine attacks (2-6 times) in the last three months. 5. Those who have moderate or severe hypertension. |
|||
| Key exclusion criteria | 1. Individuals taking an ACE inhibitor or ARB.
2. Those who fail to submit informed consent. 3. Those who may be allergic to aliskiren or candesartan. 4. SBP>180 mmHg or DBP>110 mmHg. 5. Those who are pregnant or hope to get pregnant. 6. Menstruation-related migraine patients. 7. Those who are taking cyclosporine. 8. Those who have severe hepatic dysfunction and/or renal dysfunction. 9. Those who are judged not to be eligible for entry to this study by their attending physician. |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Mamoru Shibata |
| Organization | School of Medicine, Keio University |
| Division name | Department of Neurology |
| Address | 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan |
| TEL | |
| Public contact | |
| Name of contact person | |
| Organization | School of Medicine, Keio University |
| Division name | Department of Neurology |
| Address | 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan |
| TEL | |
| Homepage URL | |
| Sponsor | |
| Institute | Department of Neurology, School of Medicine, Keio University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007516 |